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Summary. The pharmacokinetics of Isoniazid
and Rifampicin were studied in 18 patients with
mild or moderate renal failure (creatinine
clearance: 10.1-50.0 ml/min) and 17 patients
with severe renal failure (creatinine clearance
< 10.0 ml/min) and the findings compared with
those in 16 healthy subjects. The renal excretion
of Isoniazid, Acetylisoniazid, Rifampicin and
Dcsacetylrifampicin was severely inhibited in
patients with renal failure. Plasma Rifampicin
and Isoniazid concentrations in rapid acetylators
were similar in healthy subjects and both the
groups of patients. In slow acetylators, plasma
Isoniazid concentrations and exposure (AUC)
and half-life of the drug, calculated on the basis
of these concentrations were appreciably higher
in patients than in healthy subjects (P < 0.01);
the mean values in the two groups of patients
were, however, similar. The correlations between
plasma creatinine or creatinine clearance and
peak concentration, exposure or half-life of
Isoniazid were poor (r < 0.28) in the slow
acetylators. These findings suggest that in
patients with renal failure, it is not necessary to
reduce dosage of Rifampicin or of Isoniazid in
rapid acetylators but advisable in respect of
Isoniazid in slow acetylators to lessen the risk of
toxic reactions.
Introduction
Kidneys play a major role in the systemic
clearance of drugs and their metabolites. In
patients with renal failure, the elimination of
most drugs being retarded, therapeutic doses as
administered to patients with normal renal
function could lead to sustained high plasma
levels that could be toxic. The dosages of drugs
employed for treatingtuberculosis in patients
with renal failure are still largely empirical, being
about half of those administered to patients with
normal renal function. Empirical reduction could
still lead to toxic plasma levels in patients with
severe renal failure, while effective levels may not
be attained if there is a mild degree of impairment.
The difference could be accentuated in case of
Isoniazid where metabolizing enzymes display
genetic polymorphism. No information is
available, to the best of our knowledge, on the
pharmacokinetics of Rifampicin in patients with
renal failure and only a few reports concerning
Isoniazid1,2 in combined groups of slow and rapid
acetylators with no attempt made to phenotype the
patients. We, therefore, undertook a detailed study
of single-dose pharmacokinetics of these two
rugs in patients with different grades of chronic
renal failure, after classifying them as slow or
rapid acetylators to devise suitable drug dosage
schedules to be administered to such patients. The
findings were compared with those in healthy
subjects.
Material and Methods
Subjects :Patients reporting to the Nephrology
Clinic at the Government General Hospital,
Madras, were classified as having mild, moderate
or severe renal failure based on creatinine
clearance values of 20.1-50.0, 10.1-20.0 and
< 10.0 ml/min, respectively. Only patients whose
renal failure was stable, as assessed by creatinine
cl arance determined on three occasions during
the preceding week,were admitted to the
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pharmacokinetics study. The healthy subjects were
blood relatives of patients admitted for kidney
transplantation. The hepatic function, as assessed
by AST and ACT activities in plasma was normal
in all the subjects.
Determination of acetylator phenotype : The
Isoniazid acetylator phenotype was tentatively
determined on the basis of salivary concentration
of Isoniazid at 5 hours after an uniform oral dose3
of Isoniazid 100 mg, the criterion for a slow
acetylator being a concentration of Isoniazid
> 0.41 µg/ml. The classification was later
confirmed on the basis of the plasma half-life of
Isoniazid (criterion for a slow acetylator : > 2.71
hours) determined during the pharmacokinetic
investigation.
Pharmocokinetic study : On the day of the
investigation, Isoniazid 7.5 mg/kg and Rifampicin
12 mg/kg (according to the dosage schedule in
Table 1) were administered on an empty stomach
and blood was collected at 1, 2, 3, 6, 8 and 24
hours. Further, the urine excreted over the period
0-24 hours was collected and its volume
measured. Plasma from the blood specimens and
aliquots of urine were stored at –20.0C. Plasma
concentrations of Isoniazid were determined by
the method of Rao et al4 and of Rifampicin by the
plate diffusion assay of Dickinson et a15. The
concentrations of Isoniazid and Acetylisoniazid in
urine were determined by the method described
earlier6 and those of Rifampicin and
Desacctylrifampicin by a procedure involving the
separation of the two compounds by thin-layer
chromatography7. All the specimens were coded
before the estimations were undertaken. Plasma
concentrations of urea and creatinine and urine
concentrations of creatinine were determined
employing an automated blood chemistry analysis
system (Beckman ‘Astra-8’) and creatinine
clearance values calculated.
Table 1. Dosage Schedule
Body-weight Isoniazid
range (kg) (mg)
< 30.0 200
30.0-44.9 300
45.0-59.9 400
> 60.0 500
Rifampicin
(mg)
300
450
600
750
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The mean plasma peak concentration was the
geometric mean of the highest individual
conc ntrations; exposure was calculated as the
area under the time-concentration curve (AUC)
from a plot of concentration versus time as linear
co-ordinates. The rate constants for elimination
and half-life of Isoniazid and Rifampicin were
calculated from the terminal phase of the time-
concentration curves.
Student’s t-test was employed for testing the
differences between the mean values.
Results
Sixteen healthy subjects (9 male, 7 female),
aged 21 to 52 years with a mean body-weight of
50.3 kg (range : 38-64 kg) and 35 patients with
renal failure (19 male, 16 female), aged 15 to 72
years with a mean body-weight of 44.6 kg (range :
31-77 kg) were admitted to the study. The renal   
fai ure was mild in 3, moderate in 15 and severe in
17 patients. Since the number of patients with mild
renal failure was small, the findings in them were
amalgamated with those having moderate renal
failure. Of the 51 study subjects, 28 were
classified as slow and 23 as rapid acetylators on
the basis of the concentration of Isoniazid in
saliva; the corresponding numbers based on the
plasma half-life of Isoniazid were 32 and 19,
respectively (Table 2). The classification was the
same by both the procedures in 45 (88%) of the 51
Table 2. Agreement in classification as slow or rapid
acetylator between plasma half-life method and
Isoniazid concentration in saliva
Based on the
salivary
method**
Based on the Plasma
half-life method*
Slow Rapid
Total
Slow 27 1 28
Rapid 5 18 23
Total 32 19 51
* From the terminal phase of the time-concentration
curve following an oral dose of Isoniazid 7.5 mg/kg
body-weight (criterion for a slow acetylator : > 2.71
hours)
** Based on the salivary concentration of Isoniazid at 5
hours following an oral, uniform dose of Isoniazid
100 mg (criterion for a slow acetylator: > 0.41 µg/
ml).
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Table 3. Mean values and standard deviations for plasma concentrations of urea and creatinine and creatinine
clearance in healthy subjects and patients with renal failure
Group Acetylator
phenotype
Plasma
urea
(mg/dl)
Plasma
creatinine
(mg/dl)
Creatinine
clearance
(ml/min)
Healthy
Subjects
Mild or
Moderate
renal
Severe
renal
failure
Slow (10)* 21.5 + 3.1 0.82+0.22 88.1+32.8
Rapid (6) 17.8 + 8.7 0.88+0.26 82.6+ 19.0
Slow (12) 87.8 + 36.4 4.0+ 1.3 14.4+ 4.9
Rapid (6) 75.7 + 50.5 3.7 + 1.8 20.9+ 12.8
Slow (10) 138.5 + 35.2 5.8+ 1.8 6.5+ 2.1
Rapid (7) 130.4+ 37.6 6.1 +2.4 6.8+ 2.4
* Figures in parentheses indicate the number of subjects
subjects. Of the 6 misclassifications, 5 slow
    acetylators (1 healthy subject, 1 patient with mild
or moderate renal failure and 3 patients with
severe renal failure) by the plasma half-life
procedure were classified as rapid acetylators by
the saliva procedure and the converse was true in
1 healthy subject. The numbers of slow and rapid
acetylators (by the plasma half-life method) were
10 and 6 among the healthy subjects, 12 and 6
among patients with mild or moderate renal
failure and 10 and 7 among those with severe
renal failure. The mean plasma concentrations of
urea and creatinine and of creatinine, given
separately for slow and rapid acetylators are
presented in Table 3.
subjects, patients with mild or moderate renal
failure and those with severe renal failure were
7.8 and 7.7, 8.0 and 7.6 and 8.2 and 7.8 mg/kg
resp ctively; the mean dosages of Rifampicin in
he 3 groups were 11.6, 11.8 and 12.1 mg/kg,
respectively.
The distribution of subjects according to the
tim  at which the highest plasma concentrations
of Isoniazid (amalgamating the findings in slow
and rapid acetylators, as they were similar) and
Rifampicin were attained is presented in Table 4.
The rates of gastro-intestinal absorption of both
the drugs appear to be similar in all the 3 groups
and there appears to be a delay in the absorption
of Rifampicin compared with that of Isoniazid.
The mean dosages of Isoniazid administeredThe geometric mean serial plasma Isoniazid
to slow and rapid acetylators among the healthyconcentrations upto 8 hours in slow and rapid
Table 4. Distribution of healthy subjects and patients with renal failure according to highest concentrations of
Isoniazid and Rifampicin at different time points
Group Drug
1 hr
No. of subjects with highest
concentrations observed at
2 hr 3 hr 6 hr 8 hr
Total
Healthy
subjects
Isoniazid
Rifampicin
Mild or
moderate
renal failure
Severe
renal failure
Isoniazid
Rifampicin
Isoniazid
Rifampicin
13 3 – – –
16
2 11 2 1 –
14 4 – – –
18
4 11 3 – –
16 1 – – –
17
2 13 1 1 –
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acetylators in the 3 groups of subjects are depicted
in Figure 1 and those for Rifampicin in Figure 2.
The mean concentrations of Isoniazid at 24 hours
(not depicted) in slow acetylators among the
healthy subjects, patients with mild or moderate
renal failure and those with severe renal failure
were 0.2, 1.0 and 1.1 µg/ml respectively; the
corresponding concentrations in rapid acetylators
were 0.1, 0.3 and 0.2 µg/ml, respectively. The
mean Rifampicin concentrations at 24 hours in the
3 groups were 0.19, 0.17 and 0.09 µg/ml,
respectively. In slow acetylators, the mean
Isoniazid concentrations in both groups of patients
were higher than those in the healthy subjects from
the 3rd hour onwards, the differences attaining
statistical significance at 6, 8 and 24 hours (P <
0.01); none of the differences in the rapid
acetylators was significant (P > 0.2). The mean
concentrations of Rifampicin were also similar at
all time-points in the 3 groups.
The geometric mean values for peak
concentration, exposure and half-life for Isoniazid
(separately for slow and rapid acetylators) in
addition to those for Rifampicin are presented in
Table 5. In slow acetylators, the differences
between the mean values for peak concentration
were not significant; however, exposure to
Isoniazid was about 43-56% higher and the half-
life 59-85% higher in the two groups of patients
than in the healthy subjects (P < 0.001 for all).
The mean values for all 3 parameters were similar
Table 5. Some pharmacokinetic variables of Isoniazid and Rifampicin in healthy subjects and
patients with renal failure
Geometric mean (and range) of the values
Isoniazid Rifampicin
Slow acetylators Rapid acetylators
Pharmaco-
kinetic Healthy Mild or Severe Healthy Mild or Severe HealthyMild or Severe
variables subjects moderate renal subjects moderate renalsubjects moderate renal
renal failure renal failure renal failure
failure failure failure
Peak con- 11.5 10.8 10.6 6.7 6.4 7.6 15.2 13.2 11.8
centration (8.5-15.1) (8.0-13.8) (9.2-13.6) (3.9-11.0) (3.1-11.0) (5.9-8.8) (9.0-27.4) (7.0-20.0) (5.0-22.2)
µg/ml
Exposure 61 95 87 19 24 24 88 81 71
(µg/ml hours) (42-89) (63-140) (42-124) (8-28)(16-42) (16-33) (48-131) (36-138) (36-127)
Half-life 3.4 6.3 5.4 1.6 2.1 2.0 5.0 5.1 4.9
(hours) (2.7-4.2) (4.5-8.4) (2.8-7.6) (1.0-2.2) (1.6-2.7) (1.4-2.4) (2.1-9.0) (2.8-9.0) (3.4-9.8)
ISONIAZID AND RIFAMPICIN IN CHRONIC RENAL FAILURE 225
HOURS AFTER DRUG ADMINISTRATION
Fig. 2 Serial plasma Rifampicin concentrations in
values (not shown) were 1.46, 1.16, 1.12, 1.11
and 1.12 µg/ml at 1, 2, 3, 6 and 8 hours,
respectively.
in the 2 groups of patients. The mean peak
  concentrations and the mean values for exposure
and half-life for Isoniazid in rapid acetylators, and
for Rifampicin in both phenotypes were similar in
the 3 groups of subjects, and none of the
differences was significant ( P > 0.2).
The correlations between the renal function
parameters such as creatinine clearance, plasma
creatinine or urea concentrations, and the
pharmacokinetic variables, viz. the mean peak
concentration, the exposure and the half-life of
Isoniazid were examined in slow acetylators and it
was observed that the correlations were poor in all
the cases (r < 0.28).
The excretion of Isoniazid and Acetylisoniazid
in slow and rapid acetylators and those of
Rifampicin and Desacetylrifampicin in urine
excreted over a 24-hour period after drug
administration (expressed as the % of the dose of
drugs excreted) is presented in Table 6. In slow
acetylators, the excretion of both Isoniazid and
Acetylisoniazid was appreciably lower in the 2
groups of patients than in healthy subjects (P <
0.001 for both); further, the excretion of both the
compounds was lower in patients with severe renal
failure than in those with mild or moderate renal
failure (P < 0.01). In rapid acetylators, the
excretion of Isoniazid was lower in patients with
severe renal failure than that in healthy subjects
(P < 0.01); however, the difference between
healthy subjects and patients with mild or
moderate renal failure or that between the latter
Table 6. Urinary excretion of Isoniazid Acctylisoniazid, Rifampicin and Desacetylrifampicin in healthy subjects and
patients with renal failure
Drug/
metabolite
Acetylator
phenotype
Geometric mean and range of proportion
of dose (%) excreted in urine (0-24 hours)
Heal thy Patients with renal failure
Subjects
Mild or Severe
moderate
Isoniazid Slow
Rapid
Acetylisoniazid*Slow
Rapid
Rifampicin Both groups
Desacctyl- Both groups
rifampicin
*as INH equivalent.
27.0 12.8 6.9
(11.3-40.4) (5.8-18.4) (1.5-12.2)
9.1 4.6 3.2
(2.1-15.7) (1.6-14.6) (2.0-6.0)
18.1 6.2 3.8
(13.8-26.3) (4.8-16.2) (2.3-5.6)
36.6 11.4 5.3
(30.5-46.8) (3.8-51.6) (3.8-8.4)
6.3 1.9 1.4
(2.2-18.7) (0.1-5.9) (083.0)
3.6 1.1 0.7
(1.7-9.9) (0.1-2.5) (0.3-1.7)
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and patients with severe renal failure was not
significant (P > 0.2). The differences between the
3 groups in the excretion as Acetylisoniazid were
significant (P < 0.05). The excretion of
Rifampicin, either as the unchanged drug or as its
primary metabolite, Desacetylrifampicin was
significantly less in both the groups of patients
than in healthy subjects ( P < 0.001 for both); the
differences between the 2 groups of patients were,
however, not statistically significant for either
compound (P > 0.09).
Discussion
Isoniazid is eliminated from the system by
acetylation as well as renal excretion. Earlier
investigation8 in patients with normal renal
function had shown that elimination of the drug is
predominantly through acetylation (> 90% of the
dose ingested) in rapid acetylators while in slow
acetylators approximately equal proportions are
eliminated throughacetylationand renal
excretion. Therefore, the plasma concentration
and elimination half-life of Isoniazid would be
expected to remain largely unaffected by renal
failure in rapid acetylators, while the values could
be higher in slow acetylators. The results
presented in this report show that renal excretion
of Isoniazid and Acetylisoniazid is severely
inhibited among both phenotypes in patients with
renal failure. However, this inhibition results in
an increase in the plasma concentrations of
Isoniazid (from the 3rd hour onwards) in slow
acetylators only, leading to significantly higher
exposure and half-life of the drug, while it had no
effect on the peak concentration. Surprisingly, no
differences were observed between patients with
mild or moderate renal failure and those with
severe renal failure.
Peripheral neuropathy and hepatitis are the
two major reactions that can occur during
treatment with Isoniazid. It is possible that their
incidence might be altered as a result of the
increase in the exposure to Isoniazid that occurs
in slow acetylators with poor renal function.
Peripheral neuropathy occurs predominantly in
slow acetylators and is dose-related9. Any
increased tendency for it in patients with renal
failure could be prevented by administering a
small dose (6 mg) of Pyridoxin along with
Isoniazid. Among south Indian tuberculosis
patients, the incidence of hepatitis is low and
similar in slow and rapid acetylators with regimens
containing Isoniazid but not Rifampicin10;
however, with daily regimens of Isoniazid and
Rifampicin, the frequency of occurrence of this
adver e reaction was substantially higher in slow
than in rapid acetylators11. An increased risk of
hepa itis in slow acetylators with daily regimens of
Isoniazid and Rifampicin has been observed by
oth r investigatorsal o12,13. Therefore, in daily
regimens with Rifampicin, it may be advisable
to prescribe a lower than the standard dosage of
Isoniazid to slow acetylators with renal failure,
especially to light-weight patients. However, the
dosage should not be too low (not below 5 mg/
kg, in any case) as that would reduce the peak
concentration14, with which drug efficacy is
related. There is also no indication for the
reduction of larger doses (15 mg/kg) in
intermittent regimens as these are associated
with a much lower risk of hepatic toxicity11.
Since plasma concentrations in rapid acetylator  
with renal failure are fairly similar to those of
healthy subjects, the dose of Isoniazid in these
patients should be the same as for patients with
normal renal function.
Our recommendation with respect to the dosage
of Isoniazid in slow acetylators is not in line with
that of Reidenberg t al2 who in their investigation
of 8 patients with renal failure did not find any
need to reduce the dosage of this drug and
Bowersox et al1 who in 10 patients with chronic
renal failure did not recommend reduction in the
dose of Isoniazid (300 mg) in rapid acetylators and
slow acetylatorswith serum creatinine
concentration less than 12 mg/dl. However, in
patients with more severe renal failure, they too
had suggested that the dose be reduced to 200 mg.
Neither of the investigators had classified the
patients as slow or rapid acetylators.
Our findings suggest that it is desirable to do
acetylator phenotyping of patients to enable the
administration of a proper dosage of the drug.
Methods based on molar ratios of Acetylisoniazid
to Isoniazid in urine are obviously not suitable.
And, the determination of the plasma half-life of
the drug requires at least 3 collections of blood.
W  have recently shown that salivary levels of
Isoni zid are similar to those in plasma15 and
have successfully used the concentration of the
drug in saliva to determine the acetylator
phe otype of adults3 as well as children16. I  the
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current investigation, the agreement between
salivary method and the standard plasma half-life
of the drug procedure was of the order of 88%.
Of the 6 disagreements, 5 classified as slow
acetylators by the plasma half-life method were
classified as rapid acetylators by the salivary
method. If renal failure and consequent retention
of Isoniazid were the cause of the disagreement,
the converse would have been true and more rapid
acetylators would have been classified as slow
acetylators by the salivary method.
There was a significant reduction in urine
excretion of Rifampicin and Desacetylrifampicin
also in patients with renal failure, as compared
with healthy subjects. This, however, had no
effect on the plasma concentrations of the drug.
The elimination of Rifampicin is mainly through
hepato-biliary excretion17 with kidneys playing
     only a minor role. Even in healthy subjects, only
about 10-15% of the dose administered is excreted
as the drug and its primary metabolite in urine
over a 24-hour period. These findings suggest that
there is no need to reduce the dosage of
Rifampicin for tuberculous patients with renal
failure.
Renal failure on account of tuberculosis is
rare18. It is not easy to distinguish tuberculous
interstitial nephritis from non tuberculous
chronic glomerulonephritis on clinical grounds.
As has been pointed out in a leading article in
Tubercle19, renal failure due to tuberculosis is a
distinct possibility where the disease is endemic.
The findings reported in this paper could be useful
for the management with Isoniazid and Rifampicin
of tuberculosis patients with renal failure. Similar
studies with other drugs such as Streptomycin,
Pyrazinamide and Ethambutol would need to be
   undertaken as one or more of these drugs are
invariably given in combination with Isoniazid and
Rifampicin for the treatment of tuberculosis.
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